Ligand Pharma (LGND)
NASDAQ:LGND
LGND Stock Chart & Stats
$208.09
-$2.36(-2.14%)
At close: 4:00 PM EST
$208.09
-$2.36(-2.14%)
Day’s Range― - ―
52-Week Range$97.48 - $227.92
Previous CloseN/A
Volume21.09K
Average Volume (3M)227.91K
Market Cap
$4.15B
Enterprise Value$4.43B
Total Cash (Recent Filing)$733.52M
Total Debt (Recent Filing)$451.49M
Price to Earnings (P/E)29.4
Beta0.95
Next Earnings
May 06, 2026EPS Estimate
1.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.02
Shares Outstanding19,941,141
10 Day Avg. Volume191,783
30 Day Avg. Volume227,907
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.59
Price to Sales (P/S)13.64
P/FCF Ratio74.76
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue16.51
Enterprise Value/Gross Profit16.93
Enterprise Value/Ebitda22.58
Forecast
1Y Price Target
$250.17Price Target Upside20.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)8.63
Revenue Forecast (FY)$266.79M
Bulls Say, Bears Say
Bulls Say
Pipeline And Indication ExpansionAnalyst believes the market underestimates revenue potential from Filspari and other pipeline indications such as homocystinuria, implying meaningful upside if additional approvals are secured.
Regulatory Approval PathwayAnalyst expects regulatory approval of Filspari for focal segmental glomerulosclerosis based on acceptance of reduced protein in urine as an approval endpoint, which could drive strong adoption by nephrologists who treat overlapping kidney diseases.
Royalty Model And Financial FlexibilityAnalyst highlights Ligand's royalty-centric model, diversified partnered portfolio, and substantial deployable capital as foundations for stable royalty growth and the ability to pursue accretive deals.
Bears Say
Captisol Revenue VolatilityAnalyst warns that Captisol sales and related contract revenue can vary widely because of the timing of orders and milestone payments, creating unpredictable revenue swings.
Contract Revenue Predictability And Valuation RiskAnalyst notes that high variability in contract payments reduces revenue predictability and argues valuation should emphasize more stable royalty streams rather than volatile contract income.
Ligand Pharma News
LGND FAQ
What was Ligand Pharma’s price range in the past 12 months?
Ligand Pharma lowest stock price was $97.48 and its highest was $227.92 in the past 12 months.
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is $4.15B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is May 06, 2026 which is in 27 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Feb 26, 2026. The company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.497 by $0.523.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma pays a Notavailable dividend of $0.456 which represents an annual dividend yield of N/A. See more information on Ligand Pharma dividends here
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 1.84.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 19,941,141 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of $2.02 in its last earnings report, beating expectations of $1.497. Following the earnings report the stock price went up 2.498%.
Which hedge fund is a major shareholder of Ligand Pharma?
Currently, no hedge funds are holding shares in LGND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$250.17 (20.22% Upside)
$250.17 (20.22% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 33.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.25%
12-Months-Change
Fundamentals
Return on Equity
13.86%
Trailing 12-Months
Asset Growth
65.71%
Trailing 12-Months
Company Description
Ligand Pharma
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
LGND Company Deck
LGND Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, broad-based financial and operational momentum driven by a rapidly scaling royalty portfolio, sizeable deployable capital and multiple late-stage clinical and commercial catalysts (notably Palvella QTORIN, FILSPARI, Ohtuvayre and CAPVAXIVE). Key 2025 metrics showed high double-digit growth across royalties, revenue and adjusted EPS, and management provided a robust multi-year outlook (23% royalty CAGR to 2030). Headwinds are largely timing and accounting-related: an FDA review extension for FILSPARI FSGS, increased R&D/G&A due to specific investments and some 2025 one-time items that temper 2026 year-over-year comparisons. Overall, the positives materially outweigh the negatives, leaving a constructive outlook.View all LGND earnings summariesLGND Stock 12 Month Forecast
Average Price Target
$250.17
▲(20.22% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---